NCT00757692View on ClinicalTrials.gov

Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

November 30, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Vandetanib

Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously

DRUG

Bicalutamide

Bicalutamide at 50 mg will be administered orally, daily and continuously.

Trial Locations (4)

V1Y 5L3

BC Cancer Agency - Centre for Southern Interior, Kelowna

V5Z 4E6

BC Cancer Agency - Vancouver Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre, Hamilton

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

British Columbia Cancer Agency

OTHER